Shopping Cart 0
Cart Subtotal
USD 0

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Nektar Therapeutics (Nektar) carries out discovery and development of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company's technology platforms offer a wide array of functional attributes, which optimizes and enhances the profile of wide range of molecules including many classes of drugs targeting numerous disease areas. The company's products focus on various therapeutic areas, including, cancer, pain, infections and immunology among others. Its research and development activities involve peptides, proteins, antibodies, small molecule drugs, and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics (NKTR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Nektar Therapeutics, Medical Devices Deals, 2012 to YTD 2018 11

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Vaccibody Enters into Agreement with Nektar Therapeutics 13

Affimed Enters into Research Agreement with Nektar Therapeutics 14

IsoPlexis Enters into Collaboration Agreement with Nektar Therapeutics 15

Syndax Pharma Enters into Agreement with Nektar Therapeutics 16

Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 17

Bristol-Myers Squibb and Nektar Therapeutics Extend Co-Development and Commercialization Agreement for NKTR-214 18

BioXcel Therapeutics Expands Research Agreement with Nektar Therapeutics 20

Nektar Therapeutics Enters into Agreement with Takeda Pharma 21

Licensing Agreements 22

Eli Lilly Enters into Licensing Agreement with Nektar Therapeutics 22

Equity Offering 24

Nektar Therapeutics Raises USD850 Million in Private Placement of Shares 24

Nektar Therapeutics Raises USD201.8 Million in Public Offering of Shares 26

Nektar Therapeutics Completes Public Offering Of Shares For USD 124.6 Million 28

Debt Offering 29

Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 29

Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For USD 125 Million 30

Asset Transactions 32

RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 32

Acquisition 33

Nektar Therapeutics May Sell Itself 33

Nektar Therapeutics-Key Competitors 34

Nektar Therapeutics-Key Employees 35

Nektar Therapeutics-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Aug 08, 2018: Nektar Therapeutics reports financial results for the second quarter of 2018 38

May 10, 2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 40

Mar 01, 2018: Nektar Therapeutics Announces Fourth Quarter And Year-End 2017 Financial Results 43

Nov 07, 2017: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017 46

Aug 08, 2017: Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017 48

May 09, 2017: Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 49

Mar 01, 2017: Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results 51

Corporate Communications 53

Sep 01, 2018: Nektar Therapeutics strengthens Board of Directors with appointment of Veteran Biotechnology Executive Karin Eastham 53

Nov 22, 2017: Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline 54

Sep 21, 2017: Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member 55

Product News 56

11/07/2017: Data To Be Presented On Nektar's Drug Candidate NKTR-214 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting 56

09/12/2017: Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ (atezolizumab) or KEYTRUDA (pembrolizumab) 58

07/18/2017: Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain 59

06/14/2018: New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting 62

06/13/2018: Analgesic Solutions Presents Data from the Implementation of its Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS) 64

05/18/2017: Nektar Therapeutics Announces Data Presentations at ASCO 2017 66

05/03/2017: Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program 67

Product Approvals 69

May 31, 2018: Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy 69

Clinical Trials 70

Nov 11, 2017: First Data for NKTR-214 in Combination with OPDIVO (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 70

Nov 07, 2017: Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting 73

Sep 20, 2017: Nektar Therapeutics Announces Presentation on NKTR-214 at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 74

Sep 06, 2017: Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek 76

Aug 30, 2017: Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek 78

Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London 79

Jun 05, 2017: Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 80

Apr 04, 2017: Nektar Therapeutics Presents New Preclinical Data on NKTR-214 at the American Association for Cancer Research (AACR) Annual Meeting 82

Mar 27, 2017: Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders 84

Mar 20, 2017: NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain 85

Feb 18, 2017: Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium 88

Appendix 89

Methodology 89

About GlobalData 89

Contact Us 89

Disclaimer 89


List Of Figure

List of Figures

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Nektar Therapeutics, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Nektar Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nektar Therapeutics, Deals By Therapy Area, 2012 to YTD 2018 9

Nektar Therapeutics, Medical Devices Deals, 2012 to YTD 2018 11

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Vaccibody Enters into Agreement with Nektar Therapeutics 13

Affimed Enters into Research Agreement with Nektar Therapeutics 14

IsoPlexis Enters into Collaboration Agreement with Nektar Therapeutics 15

Syndax Pharma Enters into Agreement with Nektar Therapeutics 16

Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 17

Bristol-Myers Squibb and Nektar Therapeutics Extend Co-Development and Commercialization Agreement for NKTR-214 18

BioXcel Therapeutics Expands Research Agreement with Nektar Therapeutics 20

Nektar Therapeutics Enters into Agreement with Takeda Pharma 21

Eli Lilly Enters into Licensing Agreement with Nektar Therapeutics 22

Nektar Therapeutics Raises USD850 Million in Private Placement of Shares 24

Nektar Therapeutics Raises USD201.8 Million in Public Offering of Shares 26

Nektar Therapeutics Completes Public Offering Of Shares For USD 124.6 Million 28

Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 29

Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For USD 125 Million 30

RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 32

Nektar Therapeutics May Sell Itself 33

Nektar Therapeutics, Key Competitors 34

Nektar Therapeutics, Key Employees 35

Nektar Therapeutics, Other Locations 37

Nektar Therapeutics, Subsidiaries 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Nektar Therapeutics, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Nektar Therapeutics (Nektar) carries out discovery and development of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company's technology platforms offer a wide array of functional attributes, which optimizes and enhances the profile of wide range of molecules including many classes of drugs targeting numerous disease areas. The company's products focus on various therapeutic areas, including, cancer, pain, infections and immunology among others. Its research and development activities involve peptides, proteins, antibodies, small molecule drugs, and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics (NKTR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Nektar Therapeutics, Medical Devices Deals, 2012 to YTD 2018 11

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deal Details 13

Partnerships 13

Vaccibody Enters into Agreement with Nektar Therapeutics 13

Affimed Enters into Research Agreement with Nektar Therapeutics 14

IsoPlexis Enters into Collaboration Agreement with Nektar Therapeutics 15

Syndax Pharma Enters into Agreement with Nektar Therapeutics 16

Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 17

Bristol-Myers Squibb and Nektar Therapeutics Extend Co-Development and Commercialization Agreement for NKTR-214 18

BioXcel Therapeutics Expands Research Agreement with Nektar Therapeutics 20

Nektar Therapeutics Enters into Agreement with Takeda Pharma 21

Licensing Agreements 22

Eli Lilly Enters into Licensing Agreement with Nektar Therapeutics 22

Equity Offering 24

Nektar Therapeutics Raises USD850 Million in Private Placement of Shares 24

Nektar Therapeutics Raises USD201.8 Million in Public Offering of Shares 26

Nektar Therapeutics Completes Public Offering Of Shares For USD 124.6 Million 28

Debt Offering 29

Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 29

Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For USD 125 Million 30

Asset Transactions 32

RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 32

Acquisition 33

Nektar Therapeutics May Sell Itself 33

Nektar Therapeutics-Key Competitors 34

Nektar Therapeutics-Key Employees 35

Nektar Therapeutics-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Aug 08, 2018: Nektar Therapeutics reports financial results for the second quarter of 2018 38

May 10, 2018: Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 40

Mar 01, 2018: Nektar Therapeutics Announces Fourth Quarter And Year-End 2017 Financial Results 43

Nov 07, 2017: Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017 46

Aug 08, 2017: Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017 48

May 09, 2017: Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 49

Mar 01, 2017: Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results 51

Corporate Communications 53

Sep 01, 2018: Nektar Therapeutics strengthens Board of Directors with appointment of Veteran Biotechnology Executive Karin Eastham 53

Nov 22, 2017: Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline 54

Sep 21, 2017: Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member 55

Product News 56

11/07/2017: Data To Be Presented On Nektar's Drug Candidate NKTR-214 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting 56

09/12/2017: Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ (atezolizumab) or KEYTRUDA (pembrolizumab) 58

07/18/2017: Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain 59

06/14/2018: New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting 62

06/13/2018: Analgesic Solutions Presents Data from the Implementation of its Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS) 64

05/18/2017: Nektar Therapeutics Announces Data Presentations at ASCO 2017 66

05/03/2017: Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program 67

Product Approvals 69

May 31, 2018: Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy 69

Clinical Trials 70

Nov 11, 2017: First Data for NKTR-214 in Combination with OPDIVO (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 70

Nov 07, 2017: Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting 73

Sep 20, 2017: Nektar Therapeutics Announces Presentation on NKTR-214 at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting 74

Sep 06, 2017: Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek 76

Aug 30, 2017: Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek 78

Jul 10, 2017: Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London 79

Jun 05, 2017: Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 80

Apr 04, 2017: Nektar Therapeutics Presents New Preclinical Data on NKTR-214 at the American Association for Cancer Research (AACR) Annual Meeting 82

Mar 27, 2017: Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders 84

Mar 20, 2017: NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain 85

Feb 18, 2017: Clinical Data from Phase 1 Dose-Escalation Study of Single-Agent NKTR-214 in Patients with Renal Cell Carcinoma Presented at the ASCO 2017 Genitourinary Cancers Symposium 88

Appendix 89

Methodology 89

About GlobalData 89

Contact Us 89

Disclaimer 89


List Of Figure

List of Figures

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Nektar Therapeutics, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Nektar Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Nektar Therapeutics, Deals By Therapy Area, 2012 to YTD 2018 9

Nektar Therapeutics, Medical Devices Deals, 2012 to YTD 2018 11

Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Vaccibody Enters into Agreement with Nektar Therapeutics 13

Affimed Enters into Research Agreement with Nektar Therapeutics 14

IsoPlexis Enters into Collaboration Agreement with Nektar Therapeutics 15

Syndax Pharma Enters into Agreement with Nektar Therapeutics 16

Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 17

Bristol-Myers Squibb and Nektar Therapeutics Extend Co-Development and Commercialization Agreement for NKTR-214 18

BioXcel Therapeutics Expands Research Agreement with Nektar Therapeutics 20

Nektar Therapeutics Enters into Agreement with Takeda Pharma 21

Eli Lilly Enters into Licensing Agreement with Nektar Therapeutics 22

Nektar Therapeutics Raises USD850 Million in Private Placement of Shares 24

Nektar Therapeutics Raises USD201.8 Million in Public Offering of Shares 26

Nektar Therapeutics Completes Public Offering Of Shares For USD 124.6 Million 28

Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 29

Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For USD 125 Million 30

RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 32

Nektar Therapeutics May Sell Itself 33

Nektar Therapeutics, Key Competitors 34

Nektar Therapeutics, Key Employees 35

Nektar Therapeutics, Other Locations 37

Nektar Therapeutics, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Nektar Therapeutics, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.